KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Profit After Tax (2017 - 2025)

Biomarin Pharmaceutical's Profit After Tax history spans 16 years, with the latest figure at -$46.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 137.28% year-over-year to -$46.6 million, compared with a TTM value of $348.9 million through Dec 2025, down 18.26%, and an annual FY2025 reading of $348.9 million, down 18.26% over the prior year.
  • Profit After Tax for Q4 2025 was -$46.6 million at Biomarin Pharmaceutical, down from -$30.7 million in the prior quarter.
  • The five-year high for Profit After Tax was $240.5 million in Q2 2025, with the low at -$57.9 million in Q4 2021.
  • Average Profit After Tax over 5 years is $51.0 million, with a median of $34.0 million recorded in 2022.
  • Year-over-year, Profit After Tax tumbled 440.02% in 2021 and then surged 8282.73% in 2023.
  • Tracing BMRN's Profit After Tax over 5 years: stood at -$57.9 million in 2021, then soared by 99.57% to -$249000.0 in 2022, then surged by 8282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 137.28% to -$46.6 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Profit After Tax are -$46.6 million (Q4 2025), -$30.7 million (Q3 2025), and $240.5 million (Q2 2025).